Collectively, these findings demonstrate that complex II-dependent OXPHOS drives the adaptive response during glutamine deprivation, and the SDHB subunit can be exploited as an indicator of vulnerability to drug resistance in lung cancer. This evidence concerns the gene SDHB and lung cancer.